In the December 3, 2021, issue of Science, researchers reported that a missense variant that is highly enriched in the Amish population was associated with reduced levels of both LDL cholesterol and fibrinogen. To date, very few variants have been identified that affect more than one risk factor for cardiovascular disease.
Investigators at the University of Wisconsin have decreased anxiety-related behaviors in monkeys with an anxious temperament by treating them with a combination of gene therapy and low doses of the atypical antipsychotic drug clozapine, which is approved for the treatment of schizophrenia and schizoaffective disorder.
“I was not always someone who would have advertised probiotics,” Michael Otto told BioWorld. And it’s easy to see why. At this point, probiotics are more often dubious wellness offerings than evidence-based therapeutics. Part of the issue is that the mechanisms by which probiotics are supposed to exert their effects are mostly vague. Molecular mechanisms that could account for claimed health benefits are few and far between. But Otto, who is chief of the pathogen molecular genetics section at the National Institutes of Allergy and Infectious Disease, and his colleagues have identified one such molecular mechanism.
Investigators from the Ragon Institute of MGH, MIT and Harvard have reported new details on a so-called exceptional elite controller, a patient who has rid herself of an HIV infection.
In contrast to most adult mammalian tissues, the liver can regenerate itself to an impressive degree. That regeneration is critical to survival – as a key digestive organ, the liver deals with all sorts of toxins, from rotten-ish food in the wild to alcohol in more cultured settings.
Technically speaking, the scientific community as a whole cannot say for sure whether and how well Aduhelm (aducanumab, Biogen Inc./Eisai, Co., Ltd.) works. After all, two years after the initial report of the Engage and Emerge data at the 2019 Clinical Trials in Alzheimer’s Disease (CTAD), the full trial data have still not been published in a peer-reviewed publication. Which, of course, is one of the problems with Aduhelm.
Investors were thrilled when Roche Holding AG subsidiary Genentech Inc. and AC Immune SA reported top-line results from the Lauriet trial on Aug. 31, giving a positive jolt to AC Immune’s stock on the day of the announcement. At the Clinical Trials in Alzheimer’s Disease 2021 meeting, the reaction of the medical community was more skeptical.
Investigators at Northwestern University’s Feinberg School of Medicine have used a new mouse model of Parkinson’s disease to confirm a causal role for mitochondrial dysfunction in Parkinson’s disease. More surprisingly, the same model has called into question previously uncontroversial notions about the motor features that are PD’s most conspicuous feature.
The sprint of fighting COVID-19 has been in respiratory medicine. For patients who become acutely ill, the short-term danger is in respiratory failure. But increasingly, it seems like the pandemic’s marathon fight may come to be against the neurological symptoms of COVID-19.
Investigators at Northwestern University’s Feinberg School of Medicine have used a new mouse model of Parkinson’s disease to confirm a causal role for mitochondrial dysfunction in Parkinson’s disease. More surprisingly, the same model has called into question previously uncontroversial notions about the motor features that are PD’s most conspicuous feature.
